GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference

GT Biopharma, Inc. (NASDAQ: GTBP), a clinical-stage immuno-oncology company, has announced its participation in the Centurion One Capital 9th Annual Toronto Growth Conference scheduled for March 5, 2026. The company’s Executive Chairman and CEO, Michael Breen, will address the audience in various formats including presentations, panel discussions, and one-on-one investor meetings throughout the conference, which will run from 8:00 AM to 5:00 PM EDT.

GT Biopharma is advancing its proprietary TriKE® (T-cell Engager) platform, which aims to enhance the immune system's natural killer (NK) cells, substantially improving the treatment of cancer. The company has secured an exclusive worldwide license to develop and commercialize therapies utilizing this innovative TriKE® technology in collaboration with the University of Minnesota. This methodology is at the forefront of biopharmaceutical developments, targeting more effective cancer therapeutics.

Investors and stakeholders have an opportunity to engage directly with GT Biopharma representatives during the conference. Interested parties are encouraged to reach out to Centurion One Capital for potential one-on-one meetings.

As GT Biopharma moves forward, the company underscores that certain forward-looking statements, which project future results based on current estimates and expectations, are subject to a variety of risks and uncertainties. These statements may differ materially from the actual outcomes. Investors are advised to review the latest filings with the Securities and Exchange Commission for a comprehensive understanding of the company’s risk factors.

For further details, visit GT Biopharma's website or follow their announcements through various social media channels. The ongoing research and development represent GT Biopharma’s commitment to pushing the boundaries of cancer treatment through innovative science.

GT Biopharma, Inc. (NASDAQ: GTBP) is poised to capture investor attention as it prepares to present at the Centurion One Capital 9th Annual Toronto Growth Conference on March 5, 2026. With its innovative TriKE® platform, designed to enhance the efficacy of natural killer (NK) cells in cancer treatment, GT Biopharma represents an intriguing opportunity in the immuno-oncology sector, which is experiencing substantial growth.

Investors should take note of the strategic significance of this conference. The event will provide the company with a platform to interact directly with potential investors through presentations, panel discussions, and one-on-one meetings. Michael Breen, CEO of GT Biopharma, will likely emphasize the company’s unique position in clinical-stage immunotherapy and its exclusive partnership with the University of Minnesota for the development of TriKE® therapies. This collaboration could offer GT Biopharma a competitive edge, as it leverages cutting-edge research to move therapeutics from bench to bedside.

Given the clinical stage of GT Biopharma, it’s important for investors to be aware of the inherent risks associated with biopharmaceutical investments, particularly the challenges associated with trial success and regulatory approval. The landscape for immuno-oncology is rapidly evolving, with increasing competition. Therefore, the company’s ability to effectively communicate its research progress and market potential during the conference will be vital.

For potential investors, attending the conference or following updates closely can provide insights into the company’s trajectory and strategic vision. While the stock may present volatility due to its clinical-stage nature, its innovative approach could yield significant long-term returns as the demand for effective cancer therapies continues to rise. Thus, GT Biopharma merits a watchful eye in the dynamic biotech landscape.